as the subcutaneous injection. In a trial comparing subcutaneous versus intranasal sumatriptan in <span class="SearchCriteria">cluster</span> patients, injection resulted in 87% of patients experienced complete relief of pain within 15 minutes after injection compared with only 13.4% with sumatriptan nasal spray. Sumatriptan is contraindicated in patients with ischemic heart disease, uncontrolled hypertension, peripheral vascular disease, and concurrent use of another 5-HT<sub>1</sub> agonist or ergot deriv